Frontlight ResearchEarly access
CompletedPhase 1/2
Effects of Pioglitazone on Stress Reactivity and Alcohol Craving
Key facts
- Who runs it
- The University of Texas Health Science Center, Houston
- Where
- Houston, United StatesSee the site
- Trial code
- Status
- Completed
- Phase
- Phase 1/2
- People taking part
- 67 people enrolled
- Started
- 12 May 2022
- Ended
- 16 Aug 2024
- Type of study
- Interventional, 2 groupsOne group gets a placebo (a dummy treatment), for comparison.
- Treatments tested
- Pioglitazone
- Placebo
- Record updated
- 27 August 2025
Who can take part
- Age
- 18 years and older
- Sex
- Women and men
- Healthy volunteers
- Cannot take part
The registry criteria, word for word
Show all 14 criteriaShow less
Who can take part
- treatment-seeking individuals diagnosed with Alcohol Use Disorder Diagnostic (AUD) and Statistical Manual of Mental Disorders, 5th Edition (DSM-5)
- fluent in English
- past month excessive alcohol use (>7 drinks/week for woman, >14 drinks/week for men, >3 drinks/occasion for women>4 drinks/occasion for men)
- exhibit baseline measures of either 1) 8-23 on HAM-A indicative of mild to moderate anxiety, 2) 14-26 on PSS Score indicative of moderate stress, or 3) ≥2 on Drinking Motives Questionnaire (DMQ-R) questions related to drinking indicating that individuals drink at least "some of the time" to cope
- exhibit increased stress reactivity (increased physiological response and/or self-report) at the baseline stress reactivity assessment
- females will need to agree to use of barrier methods of contraception due to pioglitazone's effects on plasma concentrations of oral contraceptives
Who cannot take part
- contraindicating pioglitazone pharmacotherapy or taking contraindicated medications (e.g., CYP2C8 inhibitors or inducers, antihyperglycemic medications)
- greater than mild substance use disorder on drugs other than alcohol, nicotine, and marijuana
- medical conditions (e.g., congestive heart failure, clinically significant edema, clinically significant liver disease, hypoglycemia, diabetes, history of bladder cancer)
- have any other illness, condition, or use of medications, which in the opinion of the PI and/or admitting physician would preclude safe and/or successful completion of the study
- Exhibit severe scores on the HAM-A, PSS, or PTSD checklist (PCL-5) - may be enrolled at the discretion of the admitting physician (Dr. Weaver)
- physical dependence on alcohol (CIWAA > 10)
- contraindications for taking pioglitazone
- be pregnant, nursing, or planning on becoming pregnant during the course of the study
Where in United States
- The University of Texas Health Science Center of HoustonHouston, United States
About the trial
What the trial wants to find out
The purpose of this study is to examine the effects of pioglitazone on stress-induced relapse risk in a laboratory model and to examine the effects of pioglitazone on drinking, stress/anxiety, and alcohol craving in the natural environment
The 2 groups in the trial
- PioglitazoneTreatment being tested
- PlaceboPlacebo, for comparison
Data and sources
- Registry record
- Listed on ClinicalTrials.gov.How to verify a trial in the registry
- Record updated
- 27 August 2025